GSK Reviews Options For European Business, Adopts New Manufacturing Processes
This article was originally published in The Pink Sheet Daily
GlaxoSmithKline will implement a new £1.5 billion restructuring program to improve commercial efficiencies in Europe and adopt new manufacturing processes, following sales and profits shortfalls in 2012.
You may also be interested in...
U.S. biotech companies are showing greater interest in building commercial infrastructure in Europe, in order to bring new medicines to European customers without local partners. Switzerland is a popular location, because of its position in the center of the continent, but the presence of experienced management is also important.
GlaxoSmithKline is bundling around 50 legacy drugs comprising some £3 billion ($4.6 billion) in annual sales into a standalone global portfolio, in a “housekeeping” move that Britain’s biggest medicines maker says is needed to better prepare the group for its coming wave of new product launches.
WHO GMP revisions proposed; ICH M7 guide drafted; four CEPs withdrawn; 28th China plant added to FDA’s import alert list.